论文部分内容阅读
目的观察美罗培南对重度肺部感染的疗效及安全性。方法选取2014年3月-2015年11月医院收治的重度肺部感染患者90例,按照随机数字表法分为对照组和试验组各45例。对照组应用亚胺培南治疗,试验组应用美罗培南治疗,对比2组细菌学疗效、临床疗效、不良反应发生率。结果治疗1个疗程后,试验组细菌学总有效率为100.0%显著高于对照组的91.1%,差异有统计学意义(P<0.05)。试验组临床总有效率为95.56%显著高于对照组的82.22%,差异有统计学意义(P<0.05)。试验组不良反应发生率为2.22%略低于对照组的4.44%,差异无统计学意义(P>0.05)。结论采用美罗培南相比亚胺培南治疗重度肺部感染细菌学疗效及临床疗效好,安全性佳,值得推广及应用。
Objective To observe the efficacy and safety of Meropenem on severe pulmonary infection. Methods Ninety patients with severe pulmonary infection admitted from March 2014 to November 2015 in our hospital were divided into control group and trial group (n = 45) according to random number table. The control group was treated with imipenem, and the experimental group was treated with Meropenem. The two groups were compared on the bacteriological efficacy, clinical efficacy and incidence of adverse reactions. Results After a course of treatment, the total bacteriological efficiency of the experimental group was 100.0%, which was significantly higher than that of the control group (91.1%) (P <0.05). The total clinical effective rate was 95.56% in the experimental group was significantly higher than 82.22% in the control group, the difference was statistically significant (P <0.05). The incidence of adverse reactions in the experimental group was 2.22% slightly lower than that of the control group (4.44%), the difference was not statistically significant (P> 0.05). Conclusion Meropenem compared imipenem in the treatment of severe pulmonary infection bacteriological efficacy and good clinical efficacy, safety, and worth promoting and application.